CJC-1295 vs Ipamorelin: Differences in Evidence, Status and Regulation
CJC-1295 and Ipamorelin are compared below on structure, research stage, registered clinical studies, and regulatory status, using the same sourced data shown on each entry page. This comparison is descriptive and does not rank either peptide.
Comparison table
| Dimension | CJC-1295 | Ipamorelin |
|---|---|---|
| Category | GH secretagogue | GH secretagogue |
| Research status | Research only | Research only |
| Origin | No data | No data |
| Amino acids | No data | No data |
| Molecular weight | No data | No data |
| Overall evidence level | No data | No data |
| Human evidence rows in our table | No data | No data |
| Registered studies (ClinicalTrials.gov) | 1 | 2 |
| Most advanced registered phase | Phase 2 | Phase 2 |
| Half-life (sourced) | No data | No data |
| Status: United States | No data | No data |
| Status: European Union | No data | No data |
| Status: United Kingdom | No data | No data |
| Status: WADA (sport) | No data | No data |
Key differences
- ClinicalTrials.gov lists 1 registered studies matching CJC-1295 and 2 matching Ipamorelin.
Entry pages
Full sources, evidence tables, and regulatory details are on each entry page: CJC-1295 and Ipamorelin.
This comparison does not rank the two peptides and does not suggest that either one is appropriate for any use.